기본 정보
- CAS
118-23-0- 표준 SMILES
CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1- InChIKey
NUNIWXHYABYXKF-UHFFFAOYSA-N- 분자식
- C17H20BrNO
- 평균 분자량
- 334.2 g/mol
- 단동위원소 질량
- 333.07283
개요
Bromazine is a tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies. It has a role as an antimicrobial agent, a H1-receptor antagonist and a muscarinic antagonist. It is an organobromine compound and a tertiary amino compound. It contains a bromazine hydrochloride.
이름 및 식별자
- 우선 이름
- Bromodiphenhydramine
- IUPAC
- 2-[(4-bromophenyl)-phenylmethoxy]-N,N-dimethylethanamine
- 영어명
- N-2-(4-bromobenzhydryloxy)ethyldimethylamine
- 분자식
- C17H20BrNO
- 분자량
- 334.25
이름 및 동의어
bromodiphenhydramineBromazineBromdiphenhydramine118-23-0HistabromamineDeserolBromazinaNeo-BenadrylBromazinumDTXSID6022688beta-(p-Bromobenzhydryloxy)ethyldimethylamine2-(p-bromo-alpha-phenylbenzyloxy)-N,N-dimethylethylamine
이름 더 보기
2-[(RS)-(4-Bromophenyl)phenylmethoxy]-N,N-dimethylethanamineBromanautineBromo-BenadrylDimenhydrinate EP Impurity HDiphenhydramine EP Impurity CN-2-(4-bromobenzhydryloxy)ethyldimethylamine2-benzhydryloxy-N-(bromomethyl)-N-methylethanamine
beta-dimethylaminoethyl p-bromobenzhydryl etherT032BI7727DTXCID002688CHEBI:59177{2-[(4-bromophenyl)(phenyl)methoxy]ethyl}dimethylamineEthanamine, 2-((4-bromophenyl)phenylmethoxy)-N,N-dimethyl-Ethanamine, 2-[(4-bromophenyl)phenylmethoxy]-N,N-dimethyl-(2-((4-bromophenyl)(phenyl)methoxy)ethyl)dimethylamine
데이터베이스 식별자
- CAS
118-23-0、1808-12-4- PubChem CID
물성
구조 계산 물성
- XLogP
- 4
- 극성 표면적
- 12.5 Ų
- 수소 결합 공여자 수
- 0
- 수소 결합 수용자 수
- 2
- 회전 가능 결합 수
- 6
- 무거운 원자 수
- 20
- 형식 전하
- 0
- 복잡도
- 258
실험 및 물리화학적 성질
LogP4
Solubility3.45e-03 g/L
Human DrugsPharmaceuticals
Physical DescriptionSolid
물리화학적 성질
- 끓는 점
- 151 · 151-154 °C(Press: 0.3 Torr)
- 밀도
- 1.259 · 1.259±0.06 g/cm3(Predicted)
- 산도 계수 (pKa)
- 8.64 · pKa 8.64(H2O t = 25 c = 0.002 to 0.01) (Uncertain)
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
유해성 정보
Regulatory InformationEthanamine, 2-(4-bromophenyl)phenylmethoxy-N,N-dimethyl-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
독성 정보
Exposure RoutesWell absorbed in the digestive tract.
Toxicity SummaryBromodiphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Signs and SymptomsSigns of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
화학 및 산업
약리 정보
ATC Code
R - Respiratory system
QR - Respiratory system
Protein Binding96%
Pharmacodynamics
Bromodiphenhydramine is an antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, Bromodiphenhydramine competes with free histamine for binding at HA-receptor sites. Bromodiphenhydramine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of Bromodiphenhydramine. This anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
Mechanism of ActionBromodiphenhydramine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding.
Biological Half-Life1 to 4 hours
Metabolism/Metabolites
Hepatic (cytochrome P-450 system); some renal.
Hepatic (cytochrome P-450 system); some renal. Half Life: 1 to 4 hours
Absorption, Distribution and ExcretionWell absorbed in the digestive tract.
Cellular LocationsMembrane
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…